Literature DB >> 27712769

Genetic and Epigenetic Components of Aspirin-Exacerbated Respiratory Disease.

Amber Dahlin1, Scott T Weiss2.   

Abstract

Aspirin-exacerbated respiratory disease (AERD) severity and its clinical phenotypes are characterized by genetic variation within pathways for arachidonic acid metabolism, inflammation, and immune responses. Epigenetic effects, including DNA methylation and histone protein modification, contribute to regulation of many genes that contribute to inflammatory states in AERD. The development of noninvasive, predictive clinical tests using data from genetic, epigenetic, pharmacogenetic, and biomarker studies will improve precision medicine efforts for AERD and asthma treatment.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AERD; Biomarker; Cysteinyl leukotriene; Eosinophil; Epigenetics; Polymorphism

Mesh：

Substances：

Year:  2016        PMID： 27712769      PMCID： PMC5720138          DOI： 10.1016/j.iac.2016.06.010

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN： 0889-8561            Impact factor:   3.479


  113 in total

1.  Eicosanoids from biopsy of normal and polypous nasal mucosa.

Authors:  H W Baenkler; D Schäfer; W Hosemann
Journal:  Rhinology       Date:  1996-09       Impact factor: 3.681

2.  Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma.

Authors:  J Adamjee; Y-J Suh; H-S Park; J-H Choi; J F Penrose; B K Lam; K F Austen; A M Cazaly; S J Wilson; A P Sampson
Journal:  J Pathol       Date:  2006-07       Impact factor: 7.996

3.  Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease.

Authors:  John W Steinke; Lixia Liu; Phillip Huyett; Julie Negri; Spencer C Payne; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2013-06-24       Impact factor: 10.793

Review 4.  The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets?

Authors:  J N Sharma; L A Mohammed
Journal:  Inflammopharmacology       Date:  2006-03       Impact factor: 4.473

5.  Association analysis of FABP1 gene polymorphisms with aspirin-exacerbated respiratory disease in asthma.

Authors:  Hun Soo Chang; Jong Sook Park; Hye-Rim Shin; Byung Lae Park; Hyoung Doo Shin; Choon-Sik Park
Journal:  Exp Lung Res       Date:  2014-10-22       Impact factor: 2.459

6.  The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions.

Authors:  M P Berges-Gimeno; R A Simon; D D Stevenson
Journal:  Clin Exp Allergy       Date:  2002-10       Impact factor: 5.018

7.  Dipeptidyl-peptidase 10 as a genetic biomarker for the aspirin-exacerbated respiratory disease phenotype.

Authors:  Seung-Hyun Kim; Hyunna Choi; Moon-Gyung Yoon; Young-Min Ye; Hae-Sim Park
Journal:  Ann Allergy Asthma Immunol       Date:  2015-01-13       Impact factor: 6.347

8.  5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci.

Authors:  Kelan G Tantisira; John Lima; Jody Sylvia; Barbara Klanderman; Scott T Weiss
Journal:  Pharmacogenet Genomics       Date:  2009-03       Impact factor: 2.089

Review 9.  Pathogenesis of aspirin-exacerbated respiratory disease and reactions.

Authors:  Tanya M Laidlaw; Joshua A Boyce
Journal:  Immunol Allergy Clin North Am       Date:  2012-12-23       Impact factor: 3.479

10.  The SNP rs3128965 of HLA-DPB1 as a genetic marker of the AERD phenotype.

Authors:  Seung-Hyun Kim; Bo-Young Cho; Hyunna Choi; Eun-Soon Shin; Young-Min Ye; Jong-Eun Lee; Hae-Sim Park
Journal:  PLoS One       Date:  2014-12-23       Impact factor: 3.240
View more
  5 in total

Review 1.  Complementary Participation of Genetics and Epigenetics in Development of NSAID-exacerbated Respiratory Disease.

Authors:  Jong Uk Lee; Jong Sook Park; Hun Soo Chang; Choon Sik Park
Journal:  Allergy Asthma Immunol Res       Date:  2019-11       Impact factor: 5.764

2.  IL10 rs1800872 Is Associated with Non-Steroidal Anti-Inflammatory Drugs Exacerbated Respiratory Disease in Mexican-Mestizo Patients.

Authors:  Gandhi Fernando Pavón-Romero; Gloria Pérez-Rubio; Fernando Ramírez-Jiménez; Enrique Ambrocio-Ortiz; Cristian Rubén Merino-Camacho; Ramcés Falfán-Valencia; Luis M Teran
Journal:  Biomolecules       Date:  2020-01-07

3.  NSAID-exacerbated respiratory disease: a population study.

Authors:  Heidi Andersén; Pinja Ilmarinen; Jasmin Honkamäki; Leena E Tuomisto; Hanna Hisinger-Mölkänen; Helena Backman; Bo Lundbäck; Eva Rönmark; Tari Haahtela; Anssi Sovijärvi; Lauri Lehtimäki; Päivi Piirilä; Hannu Kankaanranta
Journal:  ERJ Open Res       Date:  2022-01-24

Review 4.  Emerging Biomarkers Beyond Leukotrienes for the Management of Nonsteroidal Anti-inflammatory Drug (NSAID)-Exacerbated Respiratory Disease.

Authors:  Hyo-In Rhyou; Young-Hee Nam; Hae-Sim Park
Journal:  Allergy Asthma Immunol Res       Date:  2022-03       Impact factor: 5.764

5.  MS4A2-rs573790 Is Associated With Aspirin-Exacerbated Respiratory Disease: Replicative Study Using a Candidate Gene Strategy.

Authors:  Gandhi F Pavón-Romero; Gloria Pérez-Rubio; Fernando Ramírez-Jiménez; Enrique Ambrocio-Ortiz; Elisé Bañuelos-Ortiz; Norma Alvarado-Franco; Karen E Xochipa-Ruiz; Elizabeth Hernández-Juárez; Beatriz A Flores-García; Ángel E Camarena; Luis M Terán; Ramcés Falfán-Valencia
Journal:  Front Genet       Date:  2018-09-11       Impact factor: 4.599
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.